N-acetylcysteine-amide - Nacuity Pharmaceuticals

Drug Profile

N-acetylcysteine-amide - Nacuity Pharmaceuticals

Alternative Names: N-acetylcysteine-amide; NACA - Nacuity Pharmaceuticals; NPI 001

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nacuity Pharmaceuticals
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 16 Jun 2017 Nacuity Pharmaceuticals plans a phase I trial for Retinitis pigmentosa (In volunteers) in Australia (ACTRN12617000911392p)
  • 18 Jan 2017 Foundation Fighting Blindness supports the clinical development of N-acetylcysteine-amide for Retinitis pigmentosa
  • 18 Jan 2017 Preclinical trials in Retinitis pigmentosa in USA (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top